Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome
- 4 March 2021
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 384 (9), 818-828
- https://doi.org/10.1056/nejmoa2008290
Abstract
The vasoconstrictor terlipressin is used for type 1 hepatorenal syndrome (HRS-1) in many parts of the world and is part of the clinical practice guidelines in Europe.Keywords
Funding Information
- Mallinckrodt Pharmaceuticals
This publication has 33 references indexed in Scilit:
- A Unified Theory of Sepsis-Induced Acute Kidney InjuryShock, 2014
- Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012Journal of Hepatology, 2013
- Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: A meta-analysisIndian Journal of Pharmacology, 2013
- Terlipressin for hepatorenal syndromePublished by Wiley ,2012
- The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative studyThe Esophagus, 2011
- The use of terlipressin during living donor liver transplantation: Effects on systemic and splanchnic hemodynamics and renal function*Critical Care Medicine, 2011
- Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosisEuropean Journal of Gastroenterology & Hepatology, 2010
- Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosisJournal of Gastroenterology and Hepatology, 2009
- Terlipressin and Albumin vs Albumin in Patients With Cirrhosis and Hepatorenal Syndrome: A Randomized StudyGastroenterology, 2008
- A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal SyndromeGastroenterology, 2008